Synergy Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference
Synergy Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference
NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals, Inc. (NAS: SGYP) , a developer of new drugs to treat gastrointestinal diseases and disorders, today announced that its President and CEO, Gary S. Jacob, Ph.D., will present at the Canaccord Genuity 33rd Annual Growth Conference being held at the Intercontinental Hotel in Boston, MA. The presentation is scheduled for Wednesday, August 14th at 4:00 p.m. (EDT).
Live audio webcast of the presentation will be available under the investor relations section of Synergy's website at www.synergypharma.com. A replay of the presentation will also be available and archived on the site for 60 days.
About Synergy Pharmaceuticals, Inc.
Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders. Synergy's lead drug, plecanatide, and next generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C ("GC-C") agonists. Plecanatide is currently in development for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. SP-333 is in development to treat patients with inflammatory bowel disease and other GI conditions. More information is available at www.synergypharma.com
Synergy Pharmaceuticals, Inc.
Media:
Gem Gokmen
Office: 212-584-7610
Mobile: 646-637-3208
ggokmen@synergypharma.com
or
Investors:
Bernard Denoyer
Office: 212-297-0020
Mobile: 203-300-8147
bdenoyer@synergypharma.com
KEYWORDS: United States North America New York
INDUSTRY KEYWORDS:
The article Synergy Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
